Konverge (Olmesartan Medoxomil, Amlodipine)

• Konverge, a combination of an ARB and a calcium‑channel blocker, is indicated for the management of high blood pressure.
• Hypertension: lowers systolic and diastolic blood pressure and helps reduce the risk of cardiovascular complications.
• Essential hypertension: provides sustained blood pressure control when monotherapy is insufficient.
• Secondary hypertension: may be added to other agents to achieve target blood pressure in resistant cases.

• Olmesartan medoxomil selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. Amlodipine, a dihydropyridine calcium‑channel blocker, inhibits calcium influx into vascular smooth‑muscle cells, promoting arterial relaxation and vasodilation. The combined actions reduce peripheral resistance and lower blood pressure.

Konverge may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Peripheral edema, especially of the ankles
• Flushing or warmth sensation
• Fatigue or tiredness
• Palpitations or irregular heartbeat

Serious or Rare Side Effects

• Angioedema, including swelling of the face, lips, tongue, or throat
• Severe hypotension leading to fainting
• Hepatic dysfunction or elevated liver enzymes
• Acute kidney injury or worsening renal function
• Myocardial infarction or chest pain in susceptible patients
• Allergic skin reactions such as rash or urticaria

• Before initiating Konverge, clinicians should assess patient‑specific factors and monitor for potential risks.
• Blood pressure monitoring: ensure adequate control and avoid excessive hypotension.
• Renal function assessment: evaluate creatinine and electrolytes, especially in patients with pre‑existing kidney disease.
• Hepatic impairment: use with caution in moderate to severe liver disease.
• Elderly patients: start at lower doses and monitor for orthostatic symptoms.
• Pregnancy: avoid use as safety in pregnancy has not been established.
• Store at room temperature: keep below 25 °C, in the original container, protected from moisture and light.

Konverge can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren (in patients with diabetes or renal impairment): risk of severe hypotension and renal dysfunction.
• Potassium‑sparing diuretics or supplements: may cause hyperkalaemia when combined with olmesartan.
• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine plasma levels, raising the risk of edema and hypotension.
• NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives (e.g., beta‑blockers, ACE inhibitors): may enhance blood‑pressure lowering, requiring dose adjustments.
• Grapefruit juice: modestly increases amlodipine exposure.
• Lithium: concurrent use may raise lithium concentrations, necessitating serum level monitoring.
• Diuretics: may potentiate electrolyte disturbances, especially potassium loss.